Inovio Pharmaceuticals Inc (INO) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Inovio Pharmaceuticals Inc

NASDAQ | INO

1.59

USD

-0.07 (-4.22%)

AT CLOSE (AS OF Apr 3, 2025)

$61M

MARKET CAP

P/E Ratio

-3.95

EPS

$13

52 Week High

$1.5

52 Week Low

LIFE SCIENCES

Sector

INO Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

INO Technicals

Tags:

INO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$39M
Total Revenue	$218K
Cost Of Revenue	$37M
Costof Goods And Services Sold	-
Operating Income	-$112M
Selling General And Administrative	$37M
Research And Development	$76M
Operating Expenses	$113M
Investment Income Net	$6.5M
Net Interest Income	$4.6M
Interest Income	$4.8M
Interest Expense	$178K
Non Interest Income	$240K
Other Non Operating Income	-$3.2M
Depreciation	$1.8M
Depreciation And Amortization	$3.1M
Income Before Tax	-$107M
Income Tax Expense	$0
Interest And Debt Expense	$178K
Net Income From Continuing Operations	-$107M
Comprehensive Income Net Of Tax	-$107M
Ebit	-$112M
Ebitda	-$104M
Net Income	-$107M

Revenue & Profitability

Earnings Performance

INO Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$113M
Total Current Assets	$98M
Cash And Cash Equivalents At Carrying Value	$66M
Cash And Short Term Investments	$94M
Inventory	-
Current Net Receivables	$1.2M
Total Non Current Assets	$14M
Property Plant Equipment	$3.7M
Accumulated Depreciation Amortization Ppe	$16M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$30M
Long Term Investments	$1.6M
Short Term Investments	$28M
Other Current Assets	$2.5B
Other Non Current Assets	$2M
Total Liabilities	$45M
Total Current Liabilities	$35M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$2.5B
Total Non Current Liabilities	$9.4M
Capital Lease Obligations	$12M
Long Term Debt	-
Current Long Term Debt	$0
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$12B
Other Current Liabilities	$33B
Other Non Current Liabilities	-
Total Shareholder Equity	$69M
Treasury Stock	-
Retained Earnings	-$1.7T
Common Stock	$36K
Common Stock Shares Outstanding	$36M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$104M
Payments For Operating Activities	$533K
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$3.4M
Change In Operating Assets	-$2.7M
Depreciation Depletion And Amortization	$1.8M
Capital Expenditures	$488K
Change In Receivables	-$1.2M
Change In Inventory	-
Profit Loss	-$107M
Cashflow From Investment	$104M
Cashflow From Financing	$51M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$36M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	$16M
Proceeds From Repurchase Of Equity	$52M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$107M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-$39M
Total Revenue	$218K
Cost Of Revenue	$37M
Costof Goods And Services Sold	-
Operating Income	-$112M
Selling General And Administrative	$37M
Research And Development	$76M
Operating Expenses	$113M
Investment Income Net	$6.5M
Net Interest Income	$4.6M
Interest Income	$4.8M
Interest Expense	$178K
Non Interest Income	$240K
Other Non Operating Income	-$3.2M
Depreciation	$1.8M
Depreciation And Amortization	$3.1M
Income Before Tax	-$107M
Income Tax Expense	$0
Interest And Debt Expense	$178K
Net Income From Continuing Operations	-$107M
Comprehensive Income Net Of Tax	-$107M
Ebit	-$112M
Ebitda	-$104M
Net Income	-$107M

INO Profile

Inovio Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

INO $1.59 (-4.22%) Quote details